SPRY
ARS Pharmaceuticals, Inc.NASDAQHealthcare$8.30+2.34%ClosedMarket Cap: $824.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
7.24
P/S
9.89
EV/EBITDA
-5.19
DCF Value
$-4.48
FCF Yield
-20.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.8%
Operating Margin
-212.9%
Net Margin
-203.3%
ROE
-100.3%
ROA
-52.3%
ROIC
-62.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $28.1M | 88.6% | $-41.5M | $-41.3M | $-0.42 | — |
| FY 2025 | $84.3M | 75.8% | $-179.4M | $-171.3M | $-1.74 | — |
| Q3 2025 | $32.5M | 74.8% | $-53.2M | $-51.2M | $-0.52 | — |
| Q2 2025 | $15.7M | 68.3% | $-47.6M | $-44.9M | $-0.46 | — |
| Q1 2025 | $8.0M | 49.3% | $-37.2M | $-33.9M | $-0.35 | — |
| Q4 2024 | $86.6M | 95.5% | $47.2M | $49.9M | $0.51 | — |
| FY 2024 | $89.1M | 76.9% | $-3.1M | $8.0M | $0.08 | — |
| Q3 2024 | $2.1M | 94.6% | $-21.7M | $-19.1M | $-0.20 | — |
| Q2 2024 | $500.0K | 100.0% | $-15.3M | $-12.5M | $-0.13 | — |
| Q1 2024 | $0.00 | -Infinity% | $-13.2M | $-10.3M | $-0.11 | — |
| Q4 2023 | $0.00 | -Infinity% | $-10.2M | $-7.2M | $-0.07 | — |
| FY 2023 | $30.0K | 100.0% | $-67.5M | $-54.4M | $-0.57 | — |